365 related articles for article (PubMed ID: 25192975)
21. Efficacy of an Adjuvanted Middle East Respiratory Syndrome Coronavirus Spike Protein Vaccine in Dromedary Camels and Alpacas.
Adney DR; Wang L; van Doremalen N; Shi W; Zhang Y; Kong WP; Miller MR; Bushmaker T; Scott D; de Wit E; Modjarrad K; Petrovsky N; Graham BS; Bowen RA; Munster VJ
Viruses; 2019 Mar; 11(3):. PubMed ID: 30832356
[TBL] [Abstract][Full Text] [Related]
22. Development of a recombinant replication-deficient rabies virus-based bivalent-vaccine against MERS-CoV and rabies virus and its humoral immunogenicity in mice.
Kato H; Takayama-Ito M; Iizuka-Shiota I; Fukushi S; Posadas-Herrera G; Horiya M; Satoh M; Yoshikawa T; Yamada S; Harada S; Fujii H; Shibamura M; Inagaki T; Morimoto K; Saijo M; Lim CK
PLoS One; 2019; 14(10):e0223684. PubMed ID: 31589656
[TBL] [Abstract][Full Text] [Related]
23. Blocking transmission of Middle East respiratory syndrome coronavirus (MERS-CoV) in llamas by vaccination with a recombinant spike protein.
Rodon J; Okba NMA; Te N; van Dieren B; Bosch BJ; Bensaid A; Segalés J; Haagmans BL; Vergara-Alert J
Emerg Microbes Infect; 2019; 8(1):1593-1603. PubMed ID: 31711379
[TBL] [Abstract][Full Text] [Related]
24. MERS-CoV spike nanoparticles protect mice from MERS-CoV infection.
Coleman CM; Venkataraman T; Liu YV; Glenn GM; Smith GE; Flyer DC; Frieman MB
Vaccine; 2017 Mar; 35(12):1586-1589. PubMed ID: 28237499
[TBL] [Abstract][Full Text] [Related]
25. Evaluation of candidate vaccine approaches for MERS-CoV.
Wang L; Shi W; Joyce MG; Modjarrad K; Zhang Y; Leung K; Lees CR; Zhou T; Yassine HM; Kanekiyo M; Yang ZY; Chen X; Becker MM; Freeman M; Vogel L; Johnson JC; Olinger G; Todd JP; Bagci U; Solomon J; Mollura DJ; Hensley L; Jahrling P; Denison MR; Rao SS; Subbarao K; Kwong PD; Mascola JR; Kong WP; Graham BS
Nat Commun; 2015 Jul; 6():7712. PubMed ID: 26218507
[TBL] [Abstract][Full Text] [Related]
26. Sero-prevalence of Middle East respiratory syndrome coronavirus (MERS-CoV) specific antibodies in dromedary camels in Tabuk, Saudi Arabia.
Harrath R; Abu Duhier FM
J Med Virol; 2018 Aug; 90(8):1285-1289. PubMed ID: 29663439
[TBL] [Abstract][Full Text] [Related]
27. Enhanced protection in mice induced by immunization with inactivated whole viruses compare to spike protein of middle east respiratory syndrome coronavirus.
Deng Y; Lan J; Bao L; Huang B; Ye F; Chen Y; Yao Y; Wang W; Qin C; Tan W
Emerg Microbes Infect; 2018 Apr; 7(1):60. PubMed ID: 29618723
[TBL] [Abstract][Full Text] [Related]
28. Intranasal vaccination with recombinant receptor-binding domain of MERS-CoV spike protein induces much stronger local mucosal immune responses than subcutaneous immunization: Implication for designing novel mucosal MERS vaccines.
Ma C; Li Y; Wang L; Zhao G; Tao X; Tseng CT; Zhou Y; Du L; Jiang S
Vaccine; 2014 Apr; 32(18):2100-8. PubMed ID: 24560617
[TBL] [Abstract][Full Text] [Related]
29. Inactivated Rabies Virus Vectored MERS-Coronavirus Vaccine Induces Protective Immunity in Mice, Camels, and Alpacas.
Chi H; Wang Y; Li E; Wang X; Wang H; Jin H; Han Q; Wang Z; Wang X; Zhu A; Sun J; Zhuang Z; Zhang L; Ye J; Wang H; Feng N; Hu M; Gao Y; Zhao J; Zhao Y; Yang S; Xia X
Front Immunol; 2022; 13():823949. PubMed ID: 35173733
[TBL] [Abstract][Full Text] [Related]
30. Live-attenuated bivalent measles virus-derived vaccines targeting Middle East respiratory syndrome coronavirus induce robust and multifunctional T cell responses against both viruses in an appropriate mouse model.
Bodmer BS; Fiedler AH; Hanauer JRH; Prüfer S; Mühlebach MD
Virology; 2018 Aug; 521():99-107. PubMed ID: 29902727
[TBL] [Abstract][Full Text] [Related]
31. Identification of an ideal adjuvant for receptor-binding domain-based subunit vaccines against Middle East respiratory syndrome coronavirus.
Zhang N; Channappanavar R; Ma C; Wang L; Tang J; Garron T; Tao X; Tasneem S; Lu L; Tseng CT; Zhou Y; Perlman S; Jiang S; Du L
Cell Mol Immunol; 2016 Mar; 13(2):180-90. PubMed ID: 25640653
[TBL] [Abstract][Full Text] [Related]
32. A Novel Nanobody Targeting Middle East Respiratory Syndrome Coronavirus (MERS-CoV) Receptor-Binding Domain Has Potent Cross-Neutralizing Activity and Protective Efficacy against MERS-CoV.
Zhao G; He L; Sun S; Qiu H; Tai W; Chen J; Li J; Chen Y; Guo Y; Wang Y; Shang J; Ji K; Fan R; Du E; Jiang S; Li F; Du L; Zhou Y
J Virol; 2018 Sep; 92(18):. PubMed ID: 29950421
[TBL] [Abstract][Full Text] [Related]
33. Middle East Respiratory Syndrome Coronavirus Antibodies in Bactrian and Hybrid Camels from Dubai.
Lau SKP; Li KSM; Luk HKH; He Z; Teng JLL; Yuen KY; Wernery U; Woo PCY
mSphere; 2020 Jan; 5(1):. PubMed ID: 31969478
[TBL] [Abstract][Full Text] [Related]
34. Nucleic acid vaccine candidates encapsulated with mesoporous silica nanoparticles against MERS-CoV.
Almansour I; Jermy BR
Hum Vaccin Immunother; 2024 Dec; 20(1):2346390. PubMed ID: 38691025
[TBL] [Abstract][Full Text] [Related]
35. Characterization and immunogenicity assessment of MERS-CoV pre-fusion spike trimeric oligomers as vaccine immunogen.
Ahuja R; Vishwakarma P; Raj S; Kumar V; Khatri R; Lohiya B; Saxena S; Kaur G; Singh G; Asthana S; Ahmed S; Samal S
Hum Vaccin Immunother; 2024 Dec; 20(1):2351664. PubMed ID: 38757508
[TBL] [Abstract][Full Text] [Related]
36. The prevalence of Middle East respiratory syndrome coronavirus (MERS-CoV) antibodies in dromedary camels in Israel.
Harcourt JL; Rudoler N; Tamin A; Leshem E; Rasis M; Giladi M; Haynes LM
Zoonoses Public Health; 2018 Sep; 65(6):749-754. PubMed ID: 29855166
[TBL] [Abstract][Full Text] [Related]
37. Middle East respiratory syndrome coronavirus (MERS-CoV) neutralising antibodies in a high-risk human population, Morocco, November 2017 to January 2018.
Abbad A; Perera RA; Anga L; Faouzi A; Minh NNT; Malik SMMR; Iounes N; Maaroufi A; Van Kerkhove MD; Peiris M; Nourlil J
Euro Surveill; 2019 Nov; 24(48):. PubMed ID: 31796154
[TBL] [Abstract][Full Text] [Related]
38. Particulate multivalent presentation of the receptor binding domain induces protective immune responses against MERS-CoV.
Okba NMA; Widjaja I; van Dieren B; Aebischer A; van Amerongen G; de Waal L; Stittelaar KJ; Schipper D; Martina B; van den Brand JMA; Beer M; Bosch BJ; Haagmans BL
Emerg Microbes Infect; 2020 Dec; 9(1):1080-1091. PubMed ID: 32471334
[TBL] [Abstract][Full Text] [Related]
39. Middle East respiratory syndrome coronavirus spike protein delivered by modified vaccinia virus Ankara efficiently induces virus-neutralizing antibodies.
Song F; Fux R; Provacia LB; Volz A; Eickmann M; Becker S; Osterhaus AD; Haagmans BL; Sutter G
J Virol; 2013 Nov; 87(21):11950-4. PubMed ID: 23986586
[TBL] [Abstract][Full Text] [Related]
40. Protective Efficacy of Recombinant Modified Vaccinia Virus Ankara Delivering Middle East Respiratory Syndrome Coronavirus Spike Glycoprotein.
Volz A; Kupke A; Song F; Jany S; Fux R; Shams-Eldin H; Schmidt J; Becker C; Eickmann M; Becker S; Sutter G
J Virol; 2015 Aug; 89(16):8651-6. PubMed ID: 26018172
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
